Is Biodexa Pharmaceuticals Plc (BDRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 95.7% / 30% | 219.6% / 30% | 94.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 95.7% / 33% | 219.6% / 33% | 94.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 4.9% / 33% | 11.3% / 33% | 4.8% / 33% | N/A | ✓ HALAL |
| S&P | 95.7% / 33% | 219.6% / 33% | 94.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 4.9% / 33% | 11.3% / 33% | 4.8% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -61.8% | |
| Return on Assets (ROA) | -39.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$12M |
| Free Cash Flow | -$13M |
| Total Debt | $727,000 |
| Debt-to-Equity | 4.4 |
| Current Ratio | 3.6 |
| Total Assets | $15M |
Price & Trading
| Last Close | $0.66 |
| 50-Day MA | $1.27 |
| 200-Day MA | $5.16 |
| Avg Volume | 323K |
| Beta | 1.0 |
|
52-Week Range
$0.65
| |
About Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Biodexa Pharmaceuticals Plc (BDRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Biodexa Pharmaceuticals Plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Biodexa Pharmaceuticals Plc's debt ratio?
Biodexa Pharmaceuticals Plc's debt ratio is 95.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.9%.
What are Biodexa Pharmaceuticals Plc's key financial metrics?
Biodexa Pharmaceuticals Plc has a market capitalization of $548,650. Return on equity stands at -61.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.